Novartis not ready to admit a $3 billion mistake

This is the online edition of Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox.

Hello! It’s so damn hot. 😥

advertisement

Apologies for the delay in delivery this morning, but I wanted to include a Novartis-pelabresib update from its earnings announcement. It’s the lead item below.

STAT+ Exclusive Story

STAT+

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Already have an account? Log in

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe